Tradestie Institutional Equity Comparison Engine

ELAB vs LSCP โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ELAB Overall Edge

ELAB Captures Institutional Edge (1โ€“1 Pillars ยท 5โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to PMGC Holdings Inc. Common Stock (ELAB) driven by superior Growth & Margin while LSCP counters with relative strength in Momentum & Technical. Fundamentally, ELAB trades at N/M Forward P/E with -470.0% operating margin (-45.8% YoY revenue) versus LSCP at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, ELAB sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against LSCP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ELAB N/M vs LSCP N/M Fwd P/E
Growth & Margin Winner ELAB
Op Margin -470.0% vs N/A ยท YoY -45.8% vs N/A
Momentum & Technical Winner LSCP
1Y -77.1% vs -3.5% ยท 52W Pos 4% vs 33%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
ELAB NASDAQ
PMGC Holdings Inc. Common Stock
Pharmaceutical Preparations
$1.14
-10.24% 1D
Market Cap $1.5M
1M Return -57.14%
1Y Return -77.09%
Forward P/E N/M
Unified AI Score
40.9 / 100 SELL
Tech 25.0 Fund 44.0 Flow 50.0 Mom 55.0
LSCP US Equity
LSCP
Institutional Equity
$24.25
+0.56% 1D
Market Cap N/A
1M Return -0.03%
1Y Return -3.49%
Forward P/E N/M
Unified AI Score
54.1 / 100 HOLD
Tech 74.0 Fund 59.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ELAB -77.09% LSCP -3.49% Spread: +5.31 pp (LSCP Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ELAB TTM Op. Margin: -470.0% LSCP TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ELAB vs LSCP. Trailing 12-month operating profitability (ELAB -470.0% vs LSCP N/A) and valuation multiples (ELAB N/M vs LSCP N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ELAB (5) vs LSCP (3)
Institutional Metric ELAB LSCP Criterion Row Winner
Market Capitalization Scale $1.5M N/A Larger Scale ELAB
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -45.8% N/A Higher Growth ELAB
Operating Margin (TTM) Profitability -470.0% N/A Higher Margin ELAB
Net Profit Margin Profitability 0.0% N/A Higher Margin ELAB
Return on Equity (ROE) Capital Efficiency -105.2% N/A Higher ROE ELAB
52-Week Range Position Momentum 4% ($1โ€“$14) 33% ($24โ€“$25) Stronger Trend LSCP
Beta / 30D Volatility Risk Regime 5.62ฮฒ ยท 102% Vol 0.01ฮฒ ยท 4% Vol Lower Realized Risk LSCP
Unified Institutional Score Composite Signal 40.9 / 100 (SELL) 54.1 / 100 (HOLD) Higher Composite LSCP

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ELAB vs LSCP Buy Guide
ELAB UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ELAB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
LSCP UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live LSCP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ELAB nor LSCP registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.